Glycopeptide vaccine based on DNA Supramolecular Hydrogels — ASN Events
  1. Schedule
  2. Poster Session 1 and Drinks
  3. Glycopeptide vaccine based on DNA Supramolecular Hydrogels

Glycopeptide vaccine based on DNA Supramolecular Hydrogels (#153)

Hongguo Hu 1 , Zhan-Yi Sun 1 , Yu Shao 2 , Yijie Wang 2 , Bo-Dou Zhang 1 , Dongsheng Liu 2 , Yan-Mei Li 1
  1. Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education) Department of Chemistry., Tsinghua University, Beijing
  2. Key Laboratory of Organic Optoelectronics and Molecular Engineering (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing

Cancer immunotherapy, which is one of the most promising ways for the treatment of cancer, has been widely developed in recent years. However, constructing a wide antigen-adaptive, easy-handling, biodegradable system that can recruit and activate antigen presenting cells (APCs) much effectively is still a challenge.

Herein, we developed an injectable DNA supramolecular hydrogel vaccine (DSHV) system which containing tumor-associated antigen MUC1 glycopeptide and immunostimulant CpG. This DSHV was three-dimensional, injectable, biocompatible, and could be self-assembly conveniently. Through simply injection, the DSHV system can mimic the function of lymph node (LN) where the APCs are recruited and activated, and then strong adaptive immune response and anti-tumor effect were elicited in vivo. Our DSHV system could serve as a general platform for cancer immunotherapy.